AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37800762 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dyspepsia prevalence in low- and middle-income countries
Number of subjects: 1000
Study 37800762 — intervention group
Group type: COMPARATOR
Intervention: Functional dyspepsia prevalence in high-income countries
Number of subjects: 1000
Study 37800762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of FD among Afro-Caribbean race
Number of subjects: 1000
Study 37800762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of FD in Sudan
Number of subjects: 1000
Study 37800762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of FD in Egypt
Number of subjects: 1000
Study 37800762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of FD in Algeria
Number of subjects: 1000
Study 37800766 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy with osimertinib
Number of subjects: 29
Study 37800887 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based Hearing Aid App (Petralex; IT4YOU Corp LLC)
Number of subjects: 38
Study 37800887 — intervention group
Group type: COMPARATOR
Intervention: Conventional Hearing Aid (Siya 1 miniRITE; Oticon A/S)
Number of subjects: 38
Study 37800887 — intervention group
Group type: COMPARATOR
Intervention: Unaided conditions
Number of subjects: 38
Study 37801046 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir inhalation
Number of subjects: 0
Study 37801046 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 37801052 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported symptom monitoring with real-time feedback to physicians
Number of subjects: 94
Study 37801052 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported symptom monitoring
Number of subjects: 94
Study 37801232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 952
Study 37801266 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan 5 mg (single oral dose)
Number of subjects: 23
Study 37801266 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy matched participants)
Number of subjects: 23
Study 37801315 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) and radiation therapy (RT) plus docetaxel
Number of subjects: 350
Study 37801356 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 144000
Study 37801356 — intervention group
Group type: COMPARATOR
Intervention: Ringer's Lactate (RL)
Number of subjects: 144000
Study 37801358 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartJournal intervention (digital tool with documentation, assessment, and education components)
Number of subjects: 0
Study 37801358 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartJournal intervention
Number of subjects: 0
Study 37801358 — intervention group
Group type: COMPARATOR
Intervention: Control group (existing oral care routines)
Number of subjects: 0
Study 37801454 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification as part of lipid-lowering therapy
Number of subjects: 0
Study 37801553 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin plus albumin
Number of subjects: 300
Study 37801553 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus albumin
Number of subjects: 300
Study 37801622 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT-III) levels at admission and at 24 hours
Number of subjects: 346
Study 37801622 — intervention group
Group type: EXPERIMENTAL
Intervention: d-dimer levels at admission and at 24 hours
Number of subjects: 346
Study 37801622 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels at 24 hours
Number of subjects: 346
Study 37801622 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine levels
Number of subjects: 346
Study 37801622 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to necrosis, infected necrosis, organ failure, and mortality
Number of subjects: 346
Study 37801622 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AT-III and high d-dimer plasma levels at 24 hours
Number of subjects: 346
Study 37801628 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab standard-dose induction treatment
Number of subjects: 201
Study 37801658 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed™ 780G Advanced Hybrid Closed-Loop System
Number of subjects: 0
Study 37801658 — intervention group
Group type: COMPARATOR
Intervention: Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections
Number of subjects: 0
Study 37801674 — intervention group
Group type: EXPERIMENTAL
Intervention: HER3-DXd 1.6-8.0 mg/kg intravenously once every 3 weeks
Number of subjects: 182
Study 37801678 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 AEs
Number of subjects: 0
Study 37801678 — intervention group
Group type: EXPERIMENTAL
Intervention: G2 AEs
Number of subjects: 0
Study 37801678 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic G2 AEs
Number of subjects: 0
Study 37801707 — intervention group
Group type: EXPERIMENTAL
Intervention: Double therapy (rituximab + chlorambucil)
Number of subjects: 401
Study 37801707 — intervention group
Group type: EXPERIMENTAL
Intervention: TTCR24
Number of subjects: 401
Study 37801707 — intervention group
Group type: EXPERIMENTAL
Intervention: CR24
Number of subjects: 401
Study 37801789 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral iron supplementation (FeSO4)
Number of subjects: 0
Study 37801936 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a nurse-led decision counselling programme
Number of subjects: 178
Study 37801936 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 178
Study 37801967 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy radiotherapy
Number of subjects: 215
Study 37801967 — intervention group
Group type: COMPARATOR
Intervention: 70 Gy radiotherapy
Number of subjects: 215
Study 37802038 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intrahippocampal delivery of cryopreserved, post-mitotic, medial ganglionic eminence (MGE) pallial-type GABAergic interneurons.
Number of subjects: 0
Study 37802088 — intervention group
Group type: EXPERIMENTAL
Intervention: Efruxifermin 28 mg
Number of subjects: 128
Study 37802088 — intervention group
Group type: EXPERIMENTAL
Intervention: Efruxifermin 50 mg
Number of subjects: 128
Study 37802088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 37802221 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging and elastography
Number of subjects: 0
Study 37802221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound elastography
Number of subjects: 0
Study 37802221 — intervention group
Group type: COMPARATOR
Intervention: Liver biopsy
Number of subjects: 0
Study 37802222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hub-and-Spoke intervention including invitation primer, mailed fecal immunochemical test, phone and text reminders, and patient navigation protocol.
Number of subjects: 5000
Study 37802222 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-intervention clinics).
Number of subjects: 5000
Study 37802222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hub-and-Spoke intervention including patient navigation protocol.
Number of subjects: 5000
Study 37802392 — intervention group
Group type: EXPERIMENTAL
Intervention: PHMB 0.02% + propamidine 0.1%
Number of subjects: 135
Study 37802392 — intervention group
Group type: COMPARATOR
Intervention: PHMB 0.08% + placebo
Number of subjects: 135
Study 37802392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 135
Study 37802566 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121 + VRC07-523LS (treatment one; n=6)
Number of subjects: 27
Study 37802566 — intervention group
Group type: EXPERIMENTAL
Intervention: PGDM1400 + VRC07-523LS (treatment two; n=6)
Number of subjects: 27
Study 37802566 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-1074 + VRC07-523LS (treatment three; n=6)
Number of subjects: 27
Study 37802566 — intervention group
Group type: EXPERIMENTAL
Intervention: PGDM1400 + PGT121 + VRC07-523LS (treatment four; n=9)
Number of subjects: 27
Study 37802566 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 27
Study 37802567 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation phase intervention (stepwise algorithm for HIV-related CNS infections, including bedside rapid diagnostic testing and WHO cryptococcal meningitis guidelines)
Number of subjects: 501
Study 37802567 — intervention group
Group type: COMPARATOR
Intervention: Observation phase (standard care)
Number of subjects: 501
Study 37802567 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation phase intervention
Number of subjects: 501
Study 37802567 — intervention group
Group type: COMPARATOR
Intervention: Observation phase
Number of subjects: 501
Study 37802608 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT) combined with chemotherapy and PD-1 inhibitor (toripalimab)
Number of subjects: 34
Study 37802611 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 0
Study 37802612 — intervention group
Group type: EXPERIMENTAL
Intervention: UroLift
Number of subjects: 45
Study 37802612 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 45
Study 37802619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapies (OATs)
Number of subjects: 32
Study 37802619 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care recruitment
Number of subjects: 32
Study 37802619 — intervention group
Group type: EXPERIMENTAL
Intervention: AF forum recruitment
Number of subjects: 32
Study 37802619 — intervention group
Group type: COMPARATOR
Intervention: Secondary care recruitment
Number of subjects: 32
Study 37802619 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 impact
Number of subjects: 32
Study 37802624 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based intervention (iVY) including video-counselling and a mobile health app
Number of subjects: 200
Study 37802679 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethine (CL) gel
Number of subjects: 123
Study 37803017 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 60
Study 37803037 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord injury patients
Number of subjects: 0
Study 37803037 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 37803096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy prior to robot-assisted therapy
Number of subjects: 37
Study 37803096 — intervention group
Group type: COMPARATOR
Intervention: Sham mirror therapy prior to robot-assisted therapy
Number of subjects: 37
Study 37803098 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-based Participant-CHW-Clinician feedback loop
Number of subjects: 134
Study 37803098 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 134
Study 37803098 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-based Participant-CHW-Clinician feedback loop (uncontrolled diabetes subgroup)
Number of subjects: 134
Study 37803098 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-based Participant-CHW-Clinician feedback loop (controlled diabetes subgroup)
Number of subjects: 134
Study 37803098 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) at-risk participants
Number of subjects: 134
Study 37803317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored approaches to care involving trusted professionals
Number of subjects: 69
Study 37803317 — intervention group
Group type: COMPARATOR
Intervention: Mainstream health services
Number of subjects: 69
Study 37803317 — intervention group
Group type: EXPERIMENTAL
Intervention: Investment in 'in-reach' services and tailored health care
Number of subjects: 69
Study 37803334 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal low-opioid anesthesia protocol (MLOP)
Number of subjects: 120
Study 37803334 — intervention group
Group type: COMPARATOR
Intervention: Routine-opioid anesthesia protocol (ROP)
Number of subjects: 120
Study 37803368 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/G) 100/6/10 µg, two inhalations twice-daily for 6 weeks after switching from high-dose ICS/LABA.
Number of subjects: 0
Study 37803368 — intervention group
Group type: COMPARATOR
Intervention: High-dose inhaled corticosteroid/long-acting β-agonist (ICS/LABA) regimen prior to switching.
Number of subjects: 0
Study 37803393 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital CBTI hubs
Number of subjects: 0
Study 37803393 — intervention group
Group type: COMPARATOR
Intervention: Insomnia care as usual (in-person or virtual)
Number of subjects: 0
Study 37803460 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabkompassen® tool (intervention group, n=553)
Number of subjects: 1106
Study 37803460 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient visit (control group, n=553)
Number of subjects: 1106
Study 37803467 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion and Mindfulness Intervention for RA (MITIG.RA) + Treatment as Usual (TAU)
Number of subjects: 0
Study 37803467 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 37803473 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression level of placental omega-3 receptors
Number of subjects: 100
Study 37803473 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and cord blood samples, placental tissue samples
Number of subjects: 100
Study 37803523 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-pembrolizumab VI-RADS 0-3
Number of subjects: 110
Study 37803759 — intervention group
Group type: COMPARATOR
Intervention: Rope-skipping exercise (2000 jumps/week)
Number of subjects: 96
Study 37803759 — intervention group
Group type: COMPARATOR
Intervention: High-fiber diet (≥20 g/d DF)
Number of subjects: 96
Study 37804162 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training using cuff weights/dumbbells at light intensity (40%-50% of maximum one repetition, 10-15 repetitions for one to three times a day) for major muscle groups of upper and lower limbs on a weekly basis.
Number of subjects: 74
Study 37804162 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy group (control group).
Number of subjects: 74
Study 37804189 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional cardiovascular risk factors
Number of subjects: 1814
Study 37804189 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and prior myocardial infarction
Number of subjects: 1814
Study 37804189 — intervention group
Group type: COMPARATOR
Intervention: Lipid-lowering treatment
Number of subjects: 1814
Study 37804189 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol levels
Number of subjects: 1814
Study 37804189 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, Black race, body mass index, type 2 diabetes, and smoking (pack years)
Number of subjects: 1814
Study 37804202 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of systolic blood pressure (SBP) by 11% to 20%
Number of subjects: 4071
Study 37804202 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of systolic blood pressure (SBP) by >20%
Number of subjects: 4071
Study 37804202 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved SBP <130 mm Hg at day 7
Number of subjects: 4071
Study 37804202 — intervention group
Group type: COMPARATOR
Intervention: Reference group of increase or no change in SBP within the first 24 hours
Number of subjects: 4071
Study 37804258 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-W
Number of subjects: 383
Study 37804258 — intervention group
Group type: COMPARATOR
Intervention: 40-W
Number of subjects: 383
Study 37804303 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person, risk-tailored social needs navigation
Number of subjects: 399
Study 37804303 — intervention group
Group type: COMPARATOR
Intervention: Preprinted resource guide
Number of subjects: 399
Study 37804303 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 399
Study 37804307 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortix therapy
Number of subjects: 21
Study 37804344 — intervention group
Group type: EXPERIMENTAL
Intervention: eculizumab
Number of subjects: 246
Study 37804344 — intervention group
Group type: EXPERIMENTAL
Intervention: ravulizumab
Number of subjects: 246
Study 37804344 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH response with Hb improvements
Number of subjects: 246
Study 37804344 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb improvements
Number of subjects: 246
Study 37804430 — intervention group
Group type: EXPERIMENTAL
Intervention: Palovarotene 20 mg (whole capsule or sprinkled on food)
Number of subjects: 23
Study 37804430 — intervention group
Group type: EXPERIMENTAL
Intervention: Palovarotene 20 mg
Number of subjects: 23
Study 37804430 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 2 mg
Number of subjects: 23
Study 37804473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 1328
Study 37804473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1328
Study 37804472 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab treatment
Number of subjects: 494
Study 37804569 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix + Apalutamide
Number of subjects: 89
Study 37804569 — intervention group
Group type: COMPARATOR
Intervention: Degarelix + Placebo
Number of subjects: 89
Study 37804674 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine (10 mg twice daily) plus physiotherapy (twice a week)
Number of subjects: 8
Study 37804674 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine plus physiotherapy
Number of subjects: 8
Study 37804674 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus physiotherapy
Number of subjects: 8
Study 37804715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal sleep longer than a person's average
Number of subjects: 119
Study 37804715 — intervention group
Group type: COMPARATOR
Intervention: Higher intraindividual sleep variability
Number of subjects: 119
Study 37804715 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer average sleep duration
Number of subjects: 119
Study 37804715 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer naps
Number of subjects: 119
Study 37804748 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (VAR)
Number of subjects: 500
Study 37804748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 500
Study 37804765 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell depletion therapy
Number of subjects: 99
Study 37804858 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart (faster aspart)
Number of subjects: 216
Study 37804858 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 216
Study 37805000 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 220
Study 37805000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 37805024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 30
Study 37805024 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 30
Study 37805216 — intervention group
Group type: EXPERIMENTAL
Intervention: MCED testing for cancer screening
Number of subjects: 6662
Study 37805456 — intervention group
Group type: EXPERIMENTAL
Intervention: Palodent plus sectional matrix system
Number of subjects: 72
Study 37805456 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimax as contact forming instrument
Number of subjects: 72
Study 37805456 — intervention group
Group type: EXPERIMENTAL
Intervention: Perform as contact forming instrument
Number of subjects: 72
Study 37805456 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact pro as contact forming instrument
Number of subjects: 72
Study 37805456 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital force gauge
Number of subjects: 72
Study 37805481 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) > 10th percentile for age
Number of subjects: 693
Study 37805481 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) > 50th percentile for age
Number of subjects: 693
Study 37805486 — intervention group
Group type: EXPERIMENTAL
Intervention: STAIRS program + Care as Usual (CAU)
Number of subjects: 140
Study 37805486 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU) + basic psychoeducation
Number of subjects: 140
Study 37805486 — intervention group
Group type: EXPERIMENTAL
Intervention: STAIRS program
Number of subjects: 140
Study 37805496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib and pyrotinib
Number of subjects: 41
Study 37805539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring for the first 72 hours after birth
Number of subjects: 1276
Study 37805539 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1276
Study 37805539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring
Number of subjects: 1276
Study 37805605 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyme honey oral rinse
Number of subjects: 28
Study 37805605 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 28
Study 37806074 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard induction chemotherapy (SIC)
Number of subjects: 10
Study 37806075 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (1000 mg/day)
Number of subjects: 1100
Study 37806075 — intervention group
Group type: EXPERIMENTAL
Intervention: Total vitamin A intake
Number of subjects: 1100
Study 37806075 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose and arachidonic acid intake
Number of subjects: 1100
Study 37806075 — intervention group
Group type: EXPERIMENTAL
Intervention: History of low birth weight, preterm birth, pre-eclampsia, and NICU admission
Number of subjects: 1100
Study 37806185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 7039
Study 37806185 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 7039
Study 37806314 — intervention group
Group type: EXPERIMENTAL
Intervention: HU6 150 mg
Number of subjects: 80